Hillhurst Biopharmaceuticals is pioneering the development of novel liquid therapeutic candidates utilizing its proprietary GLASS™ platform, which allows for the effective delivery of therapeutic gases that have traditionally been limited to inhalation methods. This innovative approach aims to unlock new treatment possibilities for various conditions, including sickle cell disease, Parkinson's disease, and acute pain. The company is focused on creating liquid drug products that can be administered orally, thereby enhancing patient accessibility and compliance. Their lead product, HBI-002, is an oral low-dose carbon monoxide therapeutic candidate specifically designed for treating sickle cell disease, while HBI-201 is an oral nitrous oxide candidate aimed at managing acute pain associated with vaso-occlusive crises in sickle cell patients.

The GLASS™ platform not only facilitates the development of these liquid therapies but also addresses significant unmet medical needs in pain management and chronic disease treatment. Hillhurst's commitment to advancing these therapeutic gases into liquid formulations represents a transformative step in biopharmaceuticals, potentially offering safer and more effective alternatives to current treatment options, such as opioids. The company is actively engaged in clinical trials to assess the safety and efficacy of its products, with ongoing collaborations with academic institutions to further enhance its research and development efforts.

United States

Hillhurst Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing technologies enabling the therapeutic use of low-dose carbon monoxide. The company is headquartered in San Diego, CA and is dedicated to developing liquid drug products containing therapeutic gases.

Hillhurst Biopharmaceuticals

Company Details